Yun Zhang serves as the Drug Safety Team Lead (DSTL) in Global Portfolio Safety at Pfizer, where she leverages over 20 years of extensive experience in nonclinical drug development to drive innovative safety strategies across a diverse range of therapeutic areas. Her role is pivotal...
Yun Zhang serves as the Drug Safety Team Lead (DSTL) in Global Portfolio Safety at Pfizer, where she leverages over 20 years of extensive experience in nonclinical drug development to drive innovative safety strategies across a diverse range of therapeutic areas. Her role is pivotal in shaping the nonclinical safety framework for projects spanning oncology, internal medicine, inflammation & immunology, rare diseases, and vaccine development. Yun is particularly focused on advancing immuno-oncology (IO) and molecularly targeted therapies, ensuring that safety assessments are integrated seamlessly into the drug development lifecycle.
As a recognized Project Toxicologist, Yun excels in collaborating with multidisciplinary project teams, where she applies her deep expertise in toxicology, pharmacology, and pharmacokinetics to deliver high-quality, evidence-based safety assessments. Her proficiency in Good Laboratory Practice (GLP) and in vivo and in vitro methodologies enables her to develop robust safety strategies that not only meet regulatory requirements but also support the overarching goals of Pfizer's therapeutic innovations.
Yun's leadership is characterized by a positive and productive approach, fostering an environment of collaboration among scientists, clinicians, and regulatory experts. She is instrumental in guiding projects from initial concept through clinical development, ensuring that safety considerations are prioritized at every stage. Her commitment to excellence and her ability to navigate complex scientific challenges make her a vital asset to Pfizer's mission of delivering safe and effective therapies to patients worldwide.
